Atox Bio Company

Established in 2003 by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. Reltecimod (AB103), the company’s lead product, is studied in Accute (Reltecimod Clinical Composite endpoint Study in necrotizing soft Tissue InfEctions), a phase 3 clinical trial in patients with Necrotizing Soft Tissue Infections, a rare, life threatening infection for which no therapy currently exists.

Headquarters: Chapel Hill, North Carolina, United States
Investor Type: N/A
Investment Stage: N/A
Employee Number: 10-50
Funding Status: Late Stage Venture
Industry: Personalized Medicine
Technology: Biotechnology, Clinical Trials, Therapeutics
Number Of Exists: N/A
Founded Date: 2003